

**FORMATO EUROPEO PER  
IL CURRICULUM VITAE**



**INFORMAZIONI PERSONALI**

Nome **BOSSA FABRIZIO**  
Indirizzo **VIA PAPA GIOVANNI XXIII – 71013 SAN GIOVANNI ROTONDO (FG) – ITALIA**  
Telefono **0882/410256**  
Fax **0882/835411**  
E-mail **f.bossaperapadrepio.it**  
Codice Fiscale **BSSFRZ73R15F839C**

Nazionalità Italiana  
Data di nascita 15/10/1973

**ESPERIENZA LAVORATIVA**

- Date  
Dal 04/05/2006 a tutt'oggi Dirigente Medico presso l'UOC di Gastroenterologia ed Endoscopia Digestiva – Ospedale "Casa Sollievo della Sofferenza" – IRCCS San Giovanni Rotondo (FG)  
Dal 04/04/2005 al 05/04/2006 Contratto di Collaborazione a Progetto per lo studio "Influenza del Genotipo sul decorso della Malattia di Crohn" presso l'Ospedale Casa Sollievo della Sofferenza" – IRCCS San Giovanni Rotondo (FG)
- Nome e indirizzo del datore di lavoro  
Ospedale "Casa Sollievo della Sofferenza" – IRCCS – Viale Cappuccini, 1 - San Giovanni Rotondo (FG)
- Principali mansioni e responsabilità  
Dirigente medico di I livello

**ISTRUZIONE E FORMAZIONE**

- Date  
Novembre 2004 Specializzazione in Gastroenterologia presso la Seconda Università degli studi di Napoli  
Novembre 2000 Laurea in Medicina e Chirurgia presso la Seconda Università degli studi di Napoli  
1992 Diploma di Maturità Liceo Scientifico Leon Battista Alberti (Napoli)
- Appartenenza a Società Scientifiche  
Socio IG-IBD (Società Italiana per lo studio delle Malattie Infiammatorie Croniche Intestinali) di cui è stato membro del Comitato coordinatore dal 02/12/2013 al dicembre 2016.
- Principali Campi di Interesse  
Si occupa in particolare di: Malattie Infiammatorie Croniche Intestinali – Videocapsula endoscopica – Ecografia addominale – Endoscopia digestiva diagnostica ed operativa
- Pubblicazioni  
Co-Autore di 64 articoli in extenso pubblicati su riviste internazionali.
- MADRELINGUA **ITALIANO**
- ALTRA LINGUA **INGLESE, GRECO**

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

#### **INGLESE/GRECO**

BUONA

BUONA

BUONA

#### CAPACITÀ E COMPETENZE ORGANIZZATIVE

*Ad es. coordinamento e amministrazione di persone, progetti, bilanci; sul posto di lavoro, in attività di volontariato (ad es. cultura e sport), a casa, ecc.*

Dal 11/2010 è referente dell'ambulatorio delle Malattie Infiammatorie Croniche Intestinali a cui è collegato un laboratorio di ricerca. In totale afferiscono all'Ambulatorio 3 medici, 1 infermiere, 2 biologi e 2 tecnici di laboratorio. Si occupa oltre che della gestione dei problemi clinici dei pazienti anche dell'organizzazione dell'ambulatorio e del coordinamento con il laboratorio di ricerca. Si occupa inoltre dell'organizzazione delle infusioni di farmaci biologici per la cura delle suddette patologie e della gestione dei trials clinici.

#### CAPACITÀ E COMPETENZE TECNICHE con computer

Buona conoscenza dell'utilizzo del Computer ed in particolare dei programmi Word, Excel, Power-Point.

#### PATENTE O PATENTI

Patente di Guida B

## ELENCO DELLE PUBBLICAZIONI

1. Fiorino G, Manetti N, Armuzzi A, Orlando A, Variola A, Bonovas S, **Bossa F**, et al. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. *Inflamm Bowel Dis*. 2017 Feb;23(2):233-243.
2. Palmieri O, **Bossa F**, et al. Crohn's Disease Localization Displays Different Predisposing Genetic Variants. *PLoS One*. 2017 Jan 4;12
3. Daperno M, Comberlato M, **Bossa F**, et al. Training Programs on Endoscopic Scoring Systems for Inflammatory Bowel Disease Lead to a Significant Increase in Interobserver Agreement Among Community Gastroenterologists. *J Crohns Colitis*. 2016 Oct 4. [Epub ahead of print]
4. Fries W, Viola A, Manetti N, Frankovic I, Pugliese D, Monterubbianesi R, Scalisi G, Aratari A, Cantoro L, Cappello M, Samperi L, Saibeni S, Casella G, Mocchi G, Rea M, Furfaro F, Contaldo A, Magarotto A, Calella F, Manguso F, Inserra G, Privitera AC, Principi M, Castiglione F, Caprioli F, Ardizzone S, Danese S, Papi C, **Bossa F**, et al. Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study". *Dig Liver Dis*. 2017 Jan;49(1):17-23.
5. Palmieri O, Mazza T, Merla A, Fusilli C, Cuttitta A, Martino G, Latiano T, Corritore G, **Bossa F**, et al. Gene expression of muscular and neuronal pathways is cooperatively dysregulated in patients with idiopathic achalasia. *Sci Rep*. 2016 Aug 11;6:31549
6. Fiorino G, Cortes PN, Ellul P, Felice C, Karatzas P, Silva M, Lakatos PL, **Bossa F**, et al. Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. *Clin Gastroenterol Hepatol*. 2016 Oct;14(10):1426-1432
7. Terracciano F, Scalisi G, **Bossa F**, et al. Transperineal ultrasonography: First level exam in IBD patients with perianal disease. *Dig Liver Dis*. 2016 Aug;48(8):874-9.
8. Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, Plevy S, Popp J, Cornillie FJ, Lukas M, Danese S, Gionchetti P, Hanauer SB, Reinisch W, Sandborn WJ, Sorrentino D, Rutgeerts P; PREVENT Study Group. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. *Gastroenterology*. 2016 Jun;150(7):1568-78.

9. **Bossa F**, et al. Letter: cytomegalovirus colitis in a patient treated with ipilimumab for metastatic melanoma. *Aliment Pharmacol Ther.* 2016 Jan;43(1):174-5.
10. Carbonnel F, Colombel JF, Filippi J, Katsanos KH, Peyrin-Biroulet L, Allez M, Nachury M, Novacek G, Danese S, Abitbol V, **Bossa F**, et al. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. *Gastroenterology.* 2016 Feb;150(2):380
11. Palmieri O, Mazzoccoli G, **Bossa F**, et al. Systematic analysis of circadian genes using genome-wide cDNA microarrays in the inflammatory bowel disease transcriptome. *Chronobiol Int.* 2015;32(7):903-16
12. Palmieri O, Creanza TM, **Bossa F**, et al. Genome-wide Pathway Analysis Using Gene Expression Data of Colonic Mucosa in Patients with Inflammatory Bowel Disease. *Inflamm Bowel Dis.* 2015 Jun;21(6):1260-8
13. Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F, Scribano ML, Armuzzi A, Caprioli F, Sturniolo GC, Rogai F, Vecchi M, Atreya R, **Bossa F**, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. *N Engl J Med.* 2015 Mar 19;372(12):1104-13.
14. Barbara G, Cremon C, Annese V, Basilisco G, Bazzoli F, Bellini M, Benedetti A, Benini L, **Bossa F**, et al. Randomised controlled trial of mesalazine in IBS. *Gut.* 2016 Jan;65(1):82-90.
15. Neri L<sup>1</sup>, Conway PM, Basilisco G Laxative Inadequate Relief Survey (LIRS) Group. Confirmatory factor analysis of the Patient Assessment of Constipation-Symptoms (PAC-SYM) among patients with chronic constipation. *Qual Life Res.* 2015 Jul;24(7):1597-605
16. Palmieri O, Mazzoccoli G, **Bossa F**, et al. Systematic analysis of circadian genes using genome-wide cDNA microarrays in the inflammatory bowel disease transcriptome. *Chronobiol Int.* 2015 Aug;32(7):903-16.
17. Palmieri O, Creanza TM, **Bossa F**, et al. Genome-wide Pathway Analysis Using Gene Expression Data of Colonic Mucosa in Patients with Inflammatory Bowel Disease. *Inflamm Bowel Dis.* 2015 Jun;21(6):1260-8.

18. Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F, Scribano ML, Armuzzi A, Caprioli F, Sturniolo GC, Rogai F, Vecchi M, Atreya R, **Bossa F**, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. *N Engl J Med*. 2015 Mar 19;372(12):1104-13.
19. Barbara G, Cremon C, Annese V, Basilisco G, Bazzoli F, Bellini M, Benedetti A, Benini L, **Bossa F**, et al. Randomised controlled trial of mesalazine in IBS. *Gut* 2014 [Epub ahead of print].
20. Daperno M, Comberlato M, **Bossa F**, et al. Inter-observer agreement in endoscopic scoring systems: Preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD). *Dig Liver Dis*. 2014 Aug[Epub ahead of print]
21. Annese V, Vecchi M; on behalf of the Italian Group for the Study of IBD (IG-IBD); IG-IBD Governing Board; IG-IBD Governing Board. Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. *Dig Liver Dis*. 2014 [Epub ahead of print].
22. Bortoli A, Daperno M, Kohn A, Politi P, Marconi S, Monterubbianesi R, Castiglione F, Corbellini A, Merli M, Casella G, D'Inca R, Orlando A, **Bossa F**, et al. Patient and physician views on the quality of care in inflammatory bowel disease: Results from SOLUTION-1, a prospective IG-IBD study. *J Crohns Colitis*. 2014 [Epub ahead of print].
23. Orlando A, Mocciaro F, Renna S, Scimeca D, Rispo A, Lia Scribano M, Testa A, Aratari A, **Bossa F**, et al. Early post-operative endoscopic recurrence in Crohn's disease patients: Data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. *J Crohns Colitis*. 2014 Oct 1;8(10):1217-21.
24. Latiano A, Palmieri O, **Bossa F**, et al. Impact of genetic polymorphisms on the pathogenesis of idiopathic achalasia: Association with IL33 gene variant.. *Hum Immunol*. 2014 Apr;75(4):364-9.
25. **Bossa F**, Annese V, Valvano MR, et al. Erythrocytes-mediated delivery of dexamethasone 21-phosphate in steroid-dependent ulcerative colitis: a randomized, double-blind Sham-controlled study. *Inflamm Bowel Dis*. 2013 Aug;19(9):1872-9.
26. Italian Group for the Study of Inflammatory Bowel Disease, Armuzzi A, Biancone L, Daperno M, Coli A, Pugliese D, Annese V, Aratari A, Ardizzone S, Balestrieri P, **Bossa F**, et al. Adalimumab in active

- ulcerative colitis: a "real-life" observational study. *Dig Liver Dis.* 2013 Sep;45(9):738-43.
27. Latiano A, Palmieri O, Pastorelli L, Vecchi M, Pizarro TT, **Bossa F**, et al. Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease. *PLoS One.* 2013 Apr 25;8(4):e62144.
  28. Andriulli A, Iacobellis A, Valvano MR, Spirito F, Ippolito A, **Bossa F**, et al. Estimates of HCV-1 Patients Attaining RVR Following Dual Therapy with Peg-Interferon and Ribavirin. *Dig Dis Sci.* 2013 May;58(5):1371-82
  29. Juran BD, Hirschfield GM, Invernizzi P, Atkinson EJ, Li Y, Xie G, Kosoy R, Ransom M, Sun Y, Bianchi I, Schlicht EM, Lleo A, Coltescu C, Bernuzzi F, Podda M, Lammert C, Shigeta R, Chan LL, Balschun T, Marconi M, Cusi D, Heathcote EJ, Mason AL, Myers RP, Milkiewicz P, Odin JA, Luketic VA, Bacon BR, Bodenheimer HC Jr, Liakina V, Vincent C, Levy C, Franke A, Gregersen PK, **Bossa F**, et al. ImmunoChip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. *Hum Mol Genet.* 2012 Dec 1;21(23):5209-5221. Epub 2012.
  30. Mazzoccoli G, Palmieri O, Corritore G, Latiano T, **Bossa F**, et al. Association study of a polymorphism in clock gene PERIOD3 and risk of inflammatory bowel disease. *Chronobiol Int.* 2012 Oct;29(8):994-1003
  31. Invernizzi P, Ransom M, Raychaudhuri S, Kosoy R, Lleo A, Shigeta R, Franke A, **Bossa F**, et al. Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. *Genes Immun.* 2012 Sep;13(6):461-8.
  32. Tavano F, di Mola FF, Latiano A, Palmieri O, **Bossa F**, et al. Neuroimmune interactions in patients with inflammatory bowel diseases: disease activity and clinical behavior based on Substance P serum levels. *J Crohns Colitis.* 2012 Jun;6(5):563-70
  33. Latiano A, Palmieri O, Latiano T, Corritore G, **Bossa F**, et al. Investigation of multiple susceptibility loci for inflammatory bowel disease in an Italian cohort of patients. *PLoS One.* 2011;6(7):e22688. Epub 2011 Jul 27.
  34. Palmieri O, Latiano A, Maglietta R, Palumbo O, Carella M, Ancona N, **Bossa F**, Andriulli A, Annese V. Dissecting the mucosal expression of human leucine-rich repeat family genes in inflammatory bowel disease

- patients. *Inflamm Bowel Dis*. 2011 Feb 1. doi: 10.1002/ibd.21614. [Epub ahead of print] PubMed PMID: 21287664.
35. Palmieri O, Latiano A, Scimeca D, **Bossa F**, Corritore G, Latiano T, Andriulli A, Annese V. IL23R, TG16L1, IRGM, OCTN1, and OCTN2 mRNA expression in inflamed and noninflamed mucosa of IBD patients. *Inflamm Bowel Dis*. 2011 Feb 1. doi: 10.1002/ibd.21613. [Epub ahead of print] PubMed PMID: 21287663.
  36. Andriulli A, Merla A, **Bossa F**, Gentile M, Biscaglia G, Caruso N. How evidence-based are current guidelines for managing patients with peptic ulcer bleeding? *World J Gastrointest Surg*. 2010 Jan 27;2(1):9-13. PubMed PMID: 21160828; PubMed Central PMCID: PMC2999192.
  37. Bertomoro P, Renna S, Cottone M, Riegler G, **Bossa F**, Giglio L, Pastorelli L, Papi C, Castiglione F, Angelucci E, Pica R, Di Paolo MC, D'Inca R. Regional variations in the use of complementary and alternative medicines (CAM) for inflammatory bowel disease patients in Italy: an IG-IBD study. *J Crohns Colitis* 2010 Sep;4(3):291-300. Epub 2010 Jan 18. PubMed PMID: 21122518.
  38. Ben-Horin S, Margalit M, Bossuyt P, Maul J, Shapira Y, Bojic D, Chermesh I, Al-Rifai A, Schoepfer A, Bosani M, Allez M, Lakatos PL, **Bossa F**, Eser A, Stefanelli T, Carbonnel F, Katsanos K, Checchin D, de Miera IS, Reinisch W, Chowers Y, Moran GW; European Crohn's and Colitis Organization (ECCO). Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and *Clostridium difficile* infection. *J Crohns Colitis*. 2010 Jun;4(2):194-8. Epub 2009 Nov 22. PubMed PMID: 21122505.
  39. Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D'Inca R, **Bossa F**, Angelucci E, Biancone L, Gionchetti P, Ardizzone S, Papi C, Fries W, Danese S, Riegler G, Cappello M, Castiglione F, Annese V, Orlando A. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. *Clin Gastroenterol Hepatol*. 2011 Jan;9(1):30-5. Epub 2010 Oct 15. PubMed PMID: 20951835.
  40. Palmieri O, Latiano A, Salvatori E, Valvano MR, **Bossa F**, Latiano T, Corritore G, di Mauro L, Andriulli A, Annese V. The -A2518G polymorphism of monocyte chemoattractant protein-1 is associated with Crohn's disease. *Am J Gastroenterol*. 2010 Jul;105(7):1586-94. Epub 2010 Feb 2. PubMed PMID: 20125127.
  41. Latiano A, Palmieri O, Corritore G, Valvano MR, **Bossa F**, Cucchiara S, Castro M, Riegler G, De Venuto D, D'Inca R, Andriulli A, Annese V.

Variants at the 3p21 locus influence susceptibility and phenotype both in adults and early-onset patients with inflammatory bowel disease. *Inflamm Bowel Dis.* 2010 Jul;16(7):1108-17. PubMed PMID: 20024904.

42. Casella G, D'Incà R, Oliva L, Daperno M, Saladino V, Zoli G, Annese V, Fries W, Cortellezzi C; Italian Group - IBD. Prevalence of celiac disease in inflammatory bowel diseases: An IG-IBD multicentre study. *Dig Liver Dis.* 2010 Mar;42(3):175-8. Epub 2009 Sep 27. PubMed PMID: 19786375.
43. Caldarola G, Annese V, **Bossa F**, Pellicano R. Linear IgA bullous dermatosis and ulcerative colitis treated by proctocolectomy. *Eur J Dermatol.* 2009 Nov-Dec;19(6):651. Epub 2009 Sep 2. PubMed PMID: 19726277.
44. Ben-Horin S, Margalit M, Bossuyt P, Maul J, Shapira Y, Bojic D, Chermesh I, Al-Rifai A, Schoepfer A, Bosani M, Allez M, Lakatos PL, **Bossa F**, Eser A, Stefanelli T, Carbonnel F, Katsanos K, Checchin D, Miera IS, Chowers Y, Moran GW; European Crohn's and Colitis Organization (ECCO). Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection. *Clin Gastroenterol Hepatol.* 2009 Sep;7(9):981-7. Epub 2009 Jun 10. PubMed PMID: 19523534.
45. Colombo E, Latiano A, Palmieri O, **Bossa F**, Andriulli A, Annese V. Enteropathic spondyloarthropathy: a common genetic background with inflammatory bowel disease? *World J Gastroenterol.* 2009 May 28;15(20):2456-62. Review. PubMed PMID: 19468994; PubMed Central PMCID: PMC2686902.
46. **Bossa F**, Colombo E, Andriulli A, Annese V. Treatment of steroid-naive ulcerative colitis. *Expert Opin Pharmacother.* 2009 Jun;10(9):1449-60. Review. PubMed PMID: 19445560.
47. Silverberg MS, Cho JH, Rioux JD, McGovern DP, Wu J, Annese V, Achkar JP, Goyette P, Scott R, Xu W, Barmada MM, Klei L, Daly MJ, Abraham C, Bayless TM, **Bossa F**, Griffiths AM, Ippoliti AF, Lahaie RG, Latiano A, Paré P, Proctor DD, Regueiro MD, Steinhart AH, Targan SR, Schumm LP, Kistner EO, Lee AT, Gregersen PK, Rotter JI, Brant SR, Taylor KD, Roeder K, Duerr RH. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. *Nat Genet.* 2009 Feb;41(2):216-20. Epub 2009 Jan 4. Erratum in: *Nat Genet.* 2009 Jun;41(6):762. PubMed PMID: 19122664; PubMed Central PMCID: PMC2652837.



48. **Bossa F**, Latiano A, Rossi L, Magnani M, Palmieri O, Dallapiccola B, Serafini S, Damonte G, De Santo E, Andriulli A, Annese V. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. *Am J Gastroenterol*. 2008 Oct;103(10):2509-16. Epub 2008 Aug 21. PubMed PMID: 18721243.
49. Latiano A, Palmieri O, Valvano MR, D'Inca R, Cucchiara S, Riegler G, Staiano AM, Ardizzone S, Accomando S, de Angelis GL, Corritore G, **Bossa F**, Annese V. Replication of interleukin 23 receptor and autophagy-related 16-like 1 association in adult- and pediatric-onset inflammatory bowel disease in Italy. *World J Gastroenterol*. 2008 Aug 7;14(29):4643-51. PubMed PMID: 18698678; PubMed Central PMCID: PMC2738788.
50. Latiano A, Palmieri O, Valvano MR, D'Inca R, Caprilli R, Cucchiara S, Sturniolo GC, **Bossa F**, Andriulli A, Annese V. The association of MYO9B gene in Italian patients with inflammatory bowel diseases. *Aliment Pharmacol Ther*. 2008 Feb 1;27(3):241-8. Epub 2007 Oct 15. PubMed PMID: 17944996.
51. Rossi L, Serafini S, Pierigé F, Castro M, Ambrosini MI, Knafelz D, Damonte G, Annese V, Latiano A, **Bossa F**, Magnani M. Erythrocytes as a controlled drug delivery system: clinical evidences. *J Control Release*. 2006 Nov 28;116(2):e43-5. PubMed PMID: 17718962.
52. Palmieri O, Latiano A, **Bossa F**, Vecchi M, D'Inca R, Guagnozzi D, Tonelli F, Cucchiara S, Valvano MR, Latiano T, Andriulli A, Annese V. Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines' toxicity and efficacy. *Aliment Pharmacol Ther*. 2007 Sep 1;26(5):737-45. Erratum in: *Aliment Pharmacol Ther*. 2007 Sep 15;26(6):968. PubMed PMID: 17697207.
53. Latiano A, Palmieri O, Valvano MR, **Bossa F**, Latiano T, Corritore G, DeSanto E, Andriulli A, Annese V. Evaluating the role of the genetic variations of PTPN22, NFKB1, and FcGRIIIA genes in inflammatory bowel disease: a meta-analysis. *Inflamm Bowel Dis*. 2007 Oct;13(10):1212-9. PubMed PMID: 17600378.
54. Cucchiara S, Latiano A, Palmieri O, Canani RB, D'Inca R, Guariso G, Vieni G, De Venuto D, Riegler G, De'Angelis GL, Guagnozzi D, Bascietto C, Miele E, Valvano MR, **Bossa F**, Annese V; Italian Society of Pediatric Gastroenterology and Nutrition. Polymorphisms of tumor necrosis factor-alpha but not MDR1 influence response to medical therapy in pediatric-

onset inflammatory bowel disease. *J Pediatr Gastroenterol Nutr.* 2007 Feb;44(2):171-9. PubMed PMID: 17255827.

55. **Bossa F**, Fiorella S, Caruso N, Accadia L, Napolitano G, Valvano MR, Andriulli A, Annese V. Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial. *Am J Gastroenterol.* 2007 Mar;102(3):601-8. PubMed PMID: 17156148.
56. Annese V, Valvano MR, Palmieri O, Latiano A, **Bossa F**, Andriulli A. Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. *World J Gastroenterol.* 2006 Jun 21;12(23):3636-44. Review. PubMed PMID: 16773678.
57. **Bossa F**, Cocomazzi G, Valvano MR, Andriulli A, Annese V. Detection of abnormal lesions recorded by capsule endoscopy. A prospective study comparing endoscopist's and nurse's accuracy. *Dig Liver Dis.* 2006 Aug;38(8):599-602. Epub 2006 Jun 5. PubMed PMID: 16750944.
58. Annese V, Latiano A, Rossi L, **Bossa F**, Damonte G, Dallapiccola B, Serafini S, Pierigé F, Andriulli A, Magnani M. The polymorphism of multi-drug resistance 1 gene (MDR1) does not influence the pharmacokinetics of dexamethasone loaded into autologous erythrocytes of patients with inflammatory bowel disease. *Eur Rev Med Pharmacol Sci.* 2006 Jan-Feb;10(1):27-31. PubMed PMID: 16494108.
59. Palmieri O, Latiano A, Valvano R, D'Inca R, Vecchi M, Sturniolo GC, Saibeni S, Peyvandi F, **Bossa F**, Zagaria C, Andriulli A, Devoto M, Annese V. Variants of OCTN1-2 cation transporter genes are associated with both Crohn's disease and ulcerative colitis. *Aliment Pharmacol Ther.* 2006 Feb 15;23(4):497-506. PubMed PMID: 16441470.
60. Palmieri O, Latiano A, Valvano R, D'Inca R, Vecchi M, Sturniolo GC, Saibeni S, **Bossa F**, Latiano T, Devoto M, Andriulli A, Annese V. Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients. *Aliment Pharmacol Ther.* 2005 Dec;22(11-12):1129-38. PubMed PMID: 16305727.
61. **Bossa F**, Caserta L, Selvaggi F, Riegler G. Infliximab in refractory severe ulcerative colitis: a case report. *Minerva Gastroenterol Dietol.* 2005 Sep;51(3):261-2. PubMed PMID: 16280968.
62. Orlando A, Colombo E, Kohn A, Biancone L, Rizzello F, Viscido A, Sostegni R, Benazzato L, Castiglione F, Papi C, Meucci G, Riegler G, Mocchiari F, Cassinotti A, Cosentino R, Geremia A, Morselli C, Angelucci E,

Lavagna A, Rispo A, **Bossa F**, Scimeca D, Cottone M; Italian Multicentric Study Group on Infliximab. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis. 2005 Aug;37(8):577-83. PubMed PMID:15886081.

63. Riegler G, Caserta L, Esposito I, De Filippo FR, **Bossa F**, Esposito P, Russo MI, Carratù R. Worse clinical course of disease in Crohn's patients with previous appendectomy. Eur J Gastroenterol Hepatol. 2005 Jun;17(6):623-7. PubMed PMID: 15879724.

64. Riegler G, **Bossa F**, Caserta L, Pera A, Tonelli F, Sturniolo GC, Oliva L, Contessini Avesani E, Poggioli G; IG-IBD Group. Colorectal cancer and high grade dysplasia complicating ulcerative colitis in Italy. A retrospective co-operative IG-IBD study. Dig Liver Dis. 2003 Sep;35(9):628-34. PubMed PMID: 14563184.

Autorizzo il trattamento dei miei dati personali ai sensi del decreto legislativo numero 196 del 30 giugno 2003

San Giovanni Rotondo, 22/02/2017

A rectangular box containing a handwritten signature in cursive script. The signature appears to read "Fabrizio Bere".